Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb

Bristol Myers Squibb to leverage Repare’s proprietary SNIPRx® synthetic lethal discovery platform to identify multiple oncology drug candidates $65 million upfront payment including $15 million in equity investment Repare Therapeutics eligible to receive development, regulatory and commercial milestones and royalties Cambridge, MA & Montreal, QC, May 26, 2020 (BUSINESS WIRE) — Repare Therapeutics Inc. (“Repare”), a…